Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan (APL-2) + Pembrolizumab +/- Bevacizumab vs Bevacizumab in Recurrent Ovarian Cancer with Malignant Effusion
NCT04919629Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2023
- Primary completion
- Apr 2028
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegcetacoplan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 cohorts), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events and Accumulation of effusion up to 3 years. Started Apr 2023; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04919629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919629.